313 related articles for article (PubMed ID: 20515312)
1. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use.
Perfetti R
Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S79-85. PubMed ID: 20515312
[TBL] [Abstract][Full Text] [Related]
2. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.
Haak T; Edelman S; Walter C; Lecointre B; Spollett G
Clin Ther; 2007 Apr; 29(4):650-60. PubMed ID: 17617288
[TBL] [Abstract][Full Text] [Related]
3. A review of insulin pen devices.
McCoy EK; Wright BM
Postgrad Med; 2010 May; 122(3):81-8. PubMed ID: 20463417
[TBL] [Abstract][Full Text] [Related]
4. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
5. A clinical and health economic review of a prefilled insulin pen.
Niskanen L
Curr Med Res Opin; 2010 Oct; 26(10):2431-9. PubMed ID: 20815660
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.
Stockl K; Ory C; Vanderplas A; Nicklasson L; Lyness W; Cobden D; Chang E
Curr Med Res Opin; 2007 Jan; 23(1):133-46. PubMed ID: 17257475
[TBL] [Abstract][Full Text] [Related]
7. Overview of insulin delivery pen devices.
Kroon L
J Am Pharm Assoc (2003); 2009; 49(5):e118-31. PubMed ID: 19692314
[TBL] [Abstract][Full Text] [Related]
8. Considerations for diabetes: treatment with insulin pen devices.
Cuddihy RM; Borgman SK
Am J Ther; 2013; 20(6):694-702. PubMed ID: 21768872
[TBL] [Abstract][Full Text] [Related]
9. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
[TBL] [Abstract][Full Text] [Related]
10. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.
Korytkowski M; Bell D; Jacobsen C; Suwannasari R;
Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308
[TBL] [Abstract][Full Text] [Related]
12. Insulin pens: the modern delivery devices.
Baruah MP
J Assoc Physicians India; 2011 Apr; 59 Suppl():38-40. PubMed ID: 21823254
[TBL] [Abstract][Full Text] [Related]
13. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
Clark PE; Valentine V; Bodie JN; Sarwat S
Curr Med Res Opin; 2010 Jul; 26(7):1745-53. PubMed ID: 20482243
[TBL] [Abstract][Full Text] [Related]
14. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
Asche CV; Shane-McWhorter L; Raparla S
Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
[TBL] [Abstract][Full Text] [Related]
15. Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
Lynch PM; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
Am J Manag Care; 2010; 16(12):892-6. PubMed ID: 21348559
[TBL] [Abstract][Full Text] [Related]
16. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
17. Addressing barriers to insulin therapy: the role of insulin pens.
Magwire ML
Am J Ther; 2011 Sep; 18(5):392-402. PubMed ID: 20838202
[TBL] [Abstract][Full Text] [Related]
18. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes.
Reimer T; Hohberg C; Pfützner AH; Jørgensen C; Jensen KH; Pfützner A
Clin Ther; 2008 Dec; 30(12):2252-62. PubMed ID: 19167585
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes.
Garg S; Kelly WC; Garg S
Expert Rev Med Devices; 2008 Mar; 5(2):113-23. PubMed ID: 18331174
[TBL] [Abstract][Full Text] [Related]
20. Dose accuracy and injection force dynamics of a novel disposable insulin pen.
Clarke A; Spollett G
Expert Opin Drug Deliv; 2007 Mar; 4(2):165-74. PubMed ID: 17335413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
